Sandbox:Ezici: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 87: Line 87:
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
===Natural History===
===Natural History===
*Without treatment or termination of pregnancy, the patient will develop symptoms of [[neonatal]] [[asphyxia]], skin [[edema]], [[pleural effusion]], [[ascites]], [[polyhydramnios]], or multiple [[malformations]], which may eventually lead to [[intrauterine]] fetal death or [[neonatal]] death.<ref name="pmid26070120">{{cite journal| author=An X, Wang J, Zhuang X, Dai J, Lu C, Li X | display-authors=etal| title=Clinical Features of Neonates with Hydrops Fetalis. | journal=Am J Perinatol | year= 2015 | volume= 32 | issue= 13 | pages= 1231-9 | pmid=26070120 | doi=10.1055/s-0035-1552934 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26070120  }} </ref>
*Patients rarely survive after the [[neonatal]] period, and some of those patients who survive, die at 1 year of age.<ref name="pmid28611934">{{cite journal| author=He S, Wang L, Pan P, Wei H, Meng D, Du J | display-authors=etal| title=Etiology and Perinatal Outcome of Nonimmune Hydrops Fetalis in Southern China. | journal=AJP Rep | year= 2017 | volume= 7 | issue= 2 | pages= e111-e115 | pmid=28611934 | doi=10.1055/s-0037-1603890 | pmc=5468117 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28611934  }} </ref>
*Although there are some patients who survived after 1 year of age with normal development, complications based on the underlying diseases might be expected.
*While approximately 68% of patients who survive after 1 year have normal development, rest of those patients diagnosed by developmental delay, mental retardation, and psychomotor retardation with marked growth failure in long-term follow-up.<ref name="pmid10090542">{{cite journal| author=Nakayama H, Kukita J, Hikino S, Nakano H, Hara T| title=Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis. | journal=Acta Paediatr | year= 1999 | volume= 88 | issue= 1 | pages= 24-8 | pmid=10090542 | doi=10.1080/08035259950170547 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10090542  }} </ref>
===Complications===
===Complications===
===Prognosis===
===Prognosis===
Prognosis is generally poor, and the mortality rate of patients with non-immune hydrops fetalis (NIHF) is approximately 43.2% at 1 year of age.<ref name="pmid28533037">{{cite journal |vauthors=Steurer MA, Peyvandi S, Baer RJ, MacKenzie T, Li BC, Norton ME, Jelliffe-Pawlowski LL, Moon-Grady AJ |title=Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset |journal=J Pediatr |volume=187 |issue= |pages=182–188.e3 |date=August 2017 |pmid=28533037 |doi=10.1016/j.jpeds.2017.04.025 |url=}}</ref>
Prognosis is generally poor, and the mortality rate of patients with non-immune hydrops fetalis (NIHF) is approximately 43.2% at 1 year of age.<ref name="pmid28533037">{{cite journal |vauthors=Steurer MA, Peyvandi S, Baer RJ, MacKenzie T, Li BC, Norton ME, Jelliffe-Pawlowski LL, Moon-Grady AJ |title=Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset |journal=J Pediatr |volume=187 |issue= |pages=182–188.e3 |date=August 2017 |pmid=28533037 |doi=10.1016/j.jpeds.2017.04.025 |url=}}</ref>

Revision as of 00:04, 1 May 2021

Hydrops Fetalis

Overview

Hydrops Fetalis indicates an excessive accumulation of interstitial fluid in extravascular compartments and body cavities which is characterized by generalized skin edema, ascites, pleural, or pericardial effusion, placental enlargement. It may be classified into two groups based on the presence or absence of rhesus iso-immunization. Although Rh disease is the major cause of immune-mediated hydrops fetalis, with the decreased prevalence of Rh disease, non-immune causes (eg, cardiovascular diseases, chromosomal abnormalities, lymphatic anomalies, hematologic diseases, etc.) are responsible in the majority of cases. Screening for Rh(D) incompatibility by Rh(D) blood typing and antibody testing are strongly recommended for all pregnant women during their first visit for pregnancy-related care. Also repeated Rh(D) antibody testing for all unsensitized Rh(D)-negative women at 24 to 28 weeks gestation is recommended, unless the biological father is known to be Rh(D) negative. Prognosis is generally poor, and the mortality rate of patients with non-immune hydrops fetalis (NIHF) is approximately 43.2% at 1 year of age, and the presence of either large birth weight, polyhydramnious, or prematurity are associated with a particularly poor prognosis among patients. to be continued...

Historical Perspective

Hydrops fetalis was first discovered by Dr. John William Ballantyne, a Scottish physician and obstetrician, in 1892.

Classification

Hydrops Fetalis may be classified into two groups based on the presence or absence of rhesus iso-immunization:

  • Immune Hydrops Fetalis
  • Non-Immune Hydrops Fetalis (NIHF)

Pathophysiology

It is thought that hydrops fetalis is caused by conditions with either increased rate of fluid transudation from the vascular compartment or decreased lymphatic return to the circulation.

Causes

Hydrops Fetalis is caused by either immune or non-immune conditions.

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Maternal risk factors in the development of non-immune hydrops fetalis (NIHF) include:[8]

Screening

  • According to the U.S. Preventive Services Task Force (USPSTF), screening for Rh(D) incompatibility by Rh(D) blood typing and antibody testing are strongly recommended for all pregnant women during their first visit for pregnancy-related care.
  • The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)-negative women at 24 to 28 weeks gestation, unless the biological father is known to be Rh(D) negative.[9]

Natural History, Complications, and Prognosis

Natural History

  • Without treatment or termination of pregnancy, the patient will develop symptoms of neonatal asphyxia, skin edema, pleural effusion, ascites, polyhydramnios, or multiple malformations, which may eventually lead to intrauterine fetal death or neonatal death.[10]
  • Patients rarely survive after the neonatal period, and some of those patients who survive, die at 1 year of age.[11]
  • Although there are some patients who survived after 1 year of age with normal development, complications based on the underlying diseases might be expected.
  • While approximately 68% of patients who survive after 1 year have normal development, rest of those patients diagnosed by developmental delay, mental retardation, and psychomotor retardation with marked growth failure in long-term follow-up.[12]

Complications

Prognosis

Prognosis is generally poor, and the mortality rate of patients with non-immune hydrops fetalis (NIHF) is approximately 43.2% at 1 year of age.[8]

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Ultrasound

An ultrasound showing a fetus with hydrops fetalis
An ultrasound showing a fetus with cystic hygroma and hydrops fetalis. Arrows pointing to bilateral pleural effusion

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

References


  1. 1.0 1.1 1.2 Vanaparthy R, Mahdy H. PMID 33085361 Check |pmid= value (help). Missing or empty |title= (help)
  2. Kontomanolis EN, Fasoulakis Z (2018). "Hydrops Fetalis and THE Parvovirus B-19". Curr Pediatr Rev. 14 (4): 239–252. doi:10.2174/1573396314666180820154340. PMID 30124157.
  3. Moise KJ (July 2005). "Red blood cell alloimmunization in pregnancy". Semin Hematol. 42 (3): 169–78. doi:10.1053/j.seminhematol.2005.04.007. PMID 16041667.
  4. Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA, Hennekam RC (May 2015). "Etiology of non-immune hydrops fetalis: An update". Am J Med Genet A. 167A (5): 1082–8. doi:10.1002/ajmg.a.36988. PMID 25712632.
  5. Bellini C, Hennekam RC (March 2012). "Non-immune hydrops fetalis: a short review of etiology and pathophysiology". Am J Med Genet A. 158A (3): 597–605. doi:10.1002/ajmg.a.34438. PMID 22302731.
  6. Hobson SR, Wallace EM, Chan YF, Edwards AG, Teoh MWT, Khaw AP (2020). "Mirroring preeclampsia: the molecular basis of Ballantyne syndrome". J Matern Fetal Neonatal Med. 33 (5): 768–773. doi:10.1080/14767058.2018.1500550. PMID 30614331.
  7. Meng, Dahua; Li, Qifei; Hu, Xuehua; Wang, Lifang; Tan, Shuyin; Su, Jiasun; Zhang, Yue; Sun, Weijia; Chen, Biyan; He, Sheng; Lin, Fei; Xie, Bobo; Chen, Shaoke; Agrawal, Pankaj B.; Luo, Shiyu; Fu, Chunyun (2019). "Etiology and Outcome of non-immune Hydrops Fetalis in Southern China: report of 1004 cases". Scientific Reports. 9 (1). doi:10.1038/s41598-019-47050-6. ISSN 2045-2322.
  8. 8.0 8.1 8.2 Steurer MA, Peyvandi S, Baer RJ, MacKenzie T, Li BC, Norton ME, Jelliffe-Pawlowski LL, Moon-Grady AJ (August 2017). "Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset". J Pediatr. 187: 182–188.e3. doi:10.1016/j.jpeds.2017.04.025. PMID 28533037.
  9. An X, Wang J, Zhuang X, Dai J, Lu C, Li X; et al. (2015). "Clinical Features of Neonates with Hydrops Fetalis". Am J Perinatol. 32 (13): 1231–9. doi:10.1055/s-0035-1552934. PMID 26070120.
  10. He S, Wang L, Pan P, Wei H, Meng D, Du J; et al. (2017). "Etiology and Perinatal Outcome of Nonimmune Hydrops Fetalis in Southern China". AJP Rep. 7 (2): e111–e115. doi:10.1055/s-0037-1603890. PMC 5468117. PMID 28611934.
  11. Nakayama H, Kukita J, Hikino S, Nakano H, Hara T (1999). "Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis". Acta Paediatr. 88 (1): 24–8. doi:10.1080/08035259950170547. PMID 10090542.